Small Bowel Cancer Treatment in Hyderabad

Overview

Understanding Small Bowel Cancer

Small bowel cancers are rare — accounting for only 1–3% of all gastrointestinal malignancies despite the small intestine constituting 75% of the GI tract’s length. They are frequently diagnosed late because symptoms are non-specific, standard colonoscopy does not visualise the small bowel, and clinician awareness is low. The main types are: adenocarcinoma (most common in duodenum/jejunum), neuroendocrine tumours (NETs, most common in ileum), gastrointestinal stromal tumours (GISTs), and lymphoma.

Small bowel NETs (carcinoid tumours) have a unique behaviour — they grow slowly but can produce serotonin and other vasoactive substances causing carcinoid syndrome (flushing, diarrhoea, wheeze). Even with liver metastases, surgical debulking provides excellent symptom control and improved survival. Hepatic cytoreduction removing ≥90% of hepatic tumour burden can significantly improve quality of life and survival.

GISTs (gastrointestinal stromal tumours) are driven by mutations in KIT or PDGFRA receptors. They are exquisitely sensitive to imatinib (Gleevec) — a targeted tyrosine kinase inhibitor. Resectable GISTs are treated with surgery; unresectable or metastatic GISTs respond dramatically to imatinib with responses lasting years. For high-risk GISTs (>5 cm, high mitotic rate), adjuvant imatinib for 3 years significantly reduces recurrence.

At a Glance

Most common types: Adenocarcinoma, NET (carcinoid), GIST, lymphoma
NET location: Most common in terminal ileum — slow-growing
GIST driver mutations: KIT (80%), PDGFRA (8%) — both imatinib-sensitive
Risk conditions: Crohn’s disease, FAP, Lynch syndrome, coeliac disease
Diagnosis challenge: CT enterography, capsule endoscopy, push enteroscopy

Warning Signs

Symptoms of Small Bowel Cancer

Small bowel cancers often present late with non-specific symptoms — a high index of suspicion is needed in at-risk patients.

😣
Abdominal Pain

Colicky or persistent central abdominal pain, often misdiagnosed as IBS for months to years.

🩸
GI Bleeding

Occult blood loss causing iron-deficiency anaemia, or overt bleeding with melaena.

🚫
Bowel Obstruction

Acute or sub-acute obstruction from intraluminal tumour or intussusception.

🔴
Carcinoid Syndrome

Flushing, diarrhoea, wheeze from serotonin-secreting NETs — typically when liver metastases are present.

⚖️
Weight Loss & Malabsorption

Progressive weight loss, malnutrition, and steatorrhoea from extensive mucosal involvement.

🔍
Incidental Finding

Small bowel tumours found on CT enterography ordered for unexplained anaemia or pain.

Our Approach

Surgical Treatment of Small Bowel Cancer

For small bowel adenocarcinoma, the surgical approach is segmental resection with adequate margins and regional mesenteric lymphadenectomy. Duodenal adenocarcinoma near the ampulla requires a Whipple’s procedure; jejunal and ileal tumours require en-bloc resection with mesentery. Adjuvant chemotherapy (CAPOX or modified FOLFOX) is recommended for Stage III disease.

For small bowel NETs, surgery remains important even in metastatic disease. Primary tumour resection prevents bowel obstruction and mesenteric desmoplasia; hepatic debulking (removing ≥90% of hepatic tumour burden) provides excellent carcinoid syndrome control. Somatostatin analogue (octreotide LAR, lanreotide) therapy controls symptoms and has antiproliferative effects. PRRT (peptide receptor radionuclide therapy) with Lu-177 dotatate is a powerful treatment for progressive NETs.

For GISTs, surgical resection is performed for all localised tumours ≥2 cm. Laparoscopic resection is suitable for tumours in favourable locations. Pre-operative imatinib for large or anatomically challenging GISTs can shrink the tumour and convert an extensive resection to a limited one. Post-operative imatinib for 3 years is standard for high-risk resected GISTs.

Surgical Procedure
Cytoreductive Surgery

En-bloc small bowel resection with mesenteric lymphadenectomy for small bowel adenocarcinoma.

Learn more →

Surgical Procedure
Whipple’s Procedure

Pancreaticoduodenectomy for periampullary and duodenal small bowel tumours.

Learn more →

Why Choose Us

Expertise You Can Trust

Dr. Mohammed Imaduddin brings internationally trained surgical skills and a patient-first philosophy to every case.

500+
Complex Oncological Surgeries Performed
15+
Years in Surgical Oncology
3
International Training Centres (Hannover, Charité, AIIMS)
FACS
Fellow of the American College of Surgeons

Common Questions

Frequently Asked Questions

Questions about small bowel tumours from patients and clinicians.

How is small bowel cancer diagnosed?
The small bowel is notoriously difficult to visualise — standard gastroscopy covers only the duodenum; colonoscopy only the terminal ileum. CT enterography or MR enterography are the primary imaging tools for evaluating the entire small bowel. Capsule endoscopy (a swallowed pill camera) visualises the mucosa; double-balloon enteroscopy allows biopsy of identified lesions. Elevated serum chromogranin A and 24-hour urinary 5-HIAA are useful for NETs. Somatostatin receptor scintigraphy (Ga-68 DOTATATE PET) is the gold standard for staging NETs.
What is carcinoid syndrome and how is it treated?
Carcinoid syndrome occurs when neuroendocrine tumour metastases — particularly liver metastases — secrete serotonin, histamine, and kinins directly into the systemic circulation. Symptoms include flushing (episodic redness of face and trunk), diarrhoea, wheeze, and abdominal cramping. Long-term, carcinoid heart disease (right-sided valvular fibrosis) can develop. Treatment: somatostatin analogues (octreotide, lanreotide) control symptoms in 60–80% of patients; hepatic debulking or embolisation for liver-dominant disease; PRRT for progressive disease.
What is GIST and how is imatinib used?
Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the GI tract, driven by activating mutations in KIT (80%) or PDGFRA (8%) genes. Imatinib (Gleevec) is a targeted tyrosine kinase inhibitor that specifically blocks the KIT and PDGFRA proteins — resulting in dramatic tumour shrinkage in 70–80% of patients. For resectable GISTs, surgery is the primary treatment; adjuvant imatinib for 3 years reduces recurrence in high-risk tumours. For metastatic or unresectable GISTs, imatinib is the first-line treatment and can control disease for years.
Does Lynch syndrome increase small bowel cancer risk?
Yes — Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC) significantly increases the risk of small bowel cancer, particularly duodenal and jejunal adenocarcinoma, with a lifetime risk of 4–7%. Other Lynch-associated cancers include colorectal, endometrial, ovarian, stomach, and urinary tract cancers. Patients with Lynch syndrome should have genetic counselling and regular surveillance, including consideration of small bowel imaging.
Can small bowel NETs with liver metastases be treated?
Yes — even with liver metastases, small bowel NETs have a much more favourable prognosis than other metastatic GI cancers. Median survival with modern treatment exceeds 5 years and can be a decade or more in low-grade tumours. Treatment options include: somatostatin analogues (antisecretory and antiproliferative), surgical debulking of liver metastases (if ≥90% can be removed), hepatic artery embolisation (TACE), and PRRT with Lu-177 DOTATATE for progressive, somatostatin receptor-positive disease.

Ready to Discuss Your Case?

Every cancer journey is different. I offer a detailed, unhurried consultation to help you understand your options and make informed decisions.

Book via WhatsApp
View Clinic Locations